India, June 16 -- Biopharmaceutical company Paratek Pharmaceuticals, Inc. (PRTK) announced Wednesday the initiation of clinical trial sites for its Phase 2b study exploring the potential utility of Nuzyra (omadacycline) as a treatment for Nontuberculous Mycobacterial (NTM) pulmonary disease caused by mycobacterium abscessus complex (MABc).
Pulmonary infections caused by MABc, an orphan disease with no FDA-approved antibiotic therapies, affects approximately 11,500 patients in the U.S. The standard of care typically involves a combination of multiple antibiotics, which can often be life-long in duration.
Nuzyra is a novel antibiotic FDA approved with both once-daily oral and intravenous (IV) formulations for the treatment of community-acqu...